1-2 of 2 results for subject:Biotechnology
Librarians' tools
- Search time
- 0.172 seconds
- Solr query time
- 0.006 seconds
- Search query
- subject:Biotechnology
- We searched for
- subject_t:Biotechnology OR subject_ses:90347
Answering member
X
Lord Boateng
Type
House
Session
Year
Department
Member
Primary member
Answering member
More
Boateng, Lord (2)
Legislative stage
Legislation
Subject
Publisher
To ask the Secretary of State for Health, what criteria will be applied to determine whether the disease transmission risks associated with xenotransplantation are of a magnitude to rule out the commencement of clinical trials.
To ask the Secretary of State for Health, what criteria will be applied to determine whether the disease transmission risks associated with xenotransplantation are of a magnitude to rule out the commencement of clinical trials.
Asked by
Norman Baker
(Liberal Democrat)
Answered by
Lord Boateng
(Labour)
Answering body
Department of Health
Type
Written questions
Status
Answered
Tabled on
24 February 1998
For answer on
27 February 1998
Answered on
27 February 1998
Mr. Baker: To ask the Secretary of State for Health what criteria will be applied to determine whether the disease transmission
risks associated with xenotransplantation are of a magnitude to rule out the commencement of clinical trials. [31686]
Mr. Boateng: The rapid rate of progress in the scientific knowledge surrounding xenotransplantation is such that any set criteria
used to determine disease transmission risks would quickly become outdated. Nevertheless, the safety of the individuals concerned
and of the public in general must be foremost in the consideration of any proposal to undertake a xenotransplantation procedure. Our
position remains that clinical trials in xenotransplantation involving humans will be allowed to take place only when we are fully
satisfied that the risks associated with such procedures are acceptable, taking account of all the available evidence at the time.
We are advised by the United Kingdom Xenotransplantation Interim Regulatory Authority (UKXIRA) on these issues and on the
acceptability of applications to undertake clinical trials in xenotransplantation involving humans. Any application will be assessed
on its own merits and will be expected to include a full assessment of the microbiological risk of the proposed procedure. The
UKXIRA will be assisted in its deliberations by independent assessors who will offer expert advice in all the relevant fields. The
Advisory Committee on Dangerous Pathogens has agreed to set up a subgroup to look at the risks of various types of xenotransplant
and will be a further source of advice to the UKXIRA.
Subjects
Biotechnology; Genetic engineering; Diseases; Medicine; Transplant surgery; Research; Xenotransplantation
Date
27 February 1998
Reference
31686; 307 c397-8W
House
House of Commons
To ask the Secretary of State for Health, if he will list the Members of the Advisory Committee on Dangerous Pathogens, indicating (a) the date on which each membership commenced, (b) those members who are employed or have been employed by companies with interests in biotechnology and (c) those members...
To ask the Secretary of State for Health, if he will list the Members of the Advisory Committee on Dangerous Pathogens, indicating (a) the date on which each membership commenced, (b) those members who are employed or have been employed by companies with interests in biotechnology and (c) those members...
Asked by
Norman Baker
(Liberal Democrat)
Answered by
Lord Boateng
(Labour)
Answering body
Department of Health
Type
Written questions
Status
Answered
Tabled on
7 January 1998
For answer on
12 January 1998
Answered on
12 January 1998
Mr. Baker: To ask the Secretary of State for Health if he will list the Members of the Advisory Committee on Dangerous Pathogens,
indicating (a) the date on which each membership commenced, (b) those members who are employed or have been employed by companies
with interests in biotechnology and (c) those members who, either individually or on behalf of groups, are known to be opposed to
xenotransplantation on ethical grounds. [22629]
Mr. Boateng: The joint Department of Health/Health and Safety Executive Advisory Committee on Dangerous Pathogens (ACDP) was
reconstituted in January 1995 for a three-year term (subsequently extended for a further 10 months). All current members, except for
the two indicated, have served on the ACDP for the full term since January 1995. The members are:
Chairman
Dr. M. J. Crumpton: Served as Chairman since 1991
Export members
Dr. B. Bannister: Member since 1993
Professor G. E. Griffin: Appointed December 1994
Professor D. J. Jeffries: Member since 1993
Dr. E. A. Gould: Member since 1991
Dr. P. W. Jones: Appointed December 1994
Dr. H. S. Tranter: Appointed December 1994
Dr. R. W. A. Girdwood: Appointed December 1994
Dr. T. D. Wyatt: Member since 1987
Employer/employee representatives
Mr. A. R. Clare: Member since 1984
Miss A. M. Harris: Member since January 1984
Ms V. Bevan: Member since May 1994
Dr. R. C. Slade: Appointed December 1994
Dr. R. Owen: Member since 1981
Mr. P. Taylor: Re-joined ACDP November 1996, served previously 1986-1990
Ms P. Smith: Appointed November 1996
Mrs. T. McGuire: Appointed December 1994
Of the expert members Dr. Bannister, Professor Griffin, Professor Jeffries, Dr. Girdwood and Dr. Wyatt are employed within the
health service. Dr. Gould is an Assistant Director at the National Environment Research Council Institute of Virology and
Environmental Microbiology. Dr. Jones is the head of the Division of Environmental Microbiology at the Institute for Animal Health.
Dr. Tranter is a microbiologist at the Centre for Applied Microbiology and Research.
In line with the tripartite principle of all Health and Safety Commission Advisory Committees, employer and employee representatives
were nominated by the Confederation of British Industry, The Public Health Laboratory Service (PHLS) Board, the Committee of Vice
Chancellors and Principals, the Trades Union Congress and the Royal College of Nursing. Mr. Clare is under contract to his former
employer, SmithKline Beecham and Miss Harris is the Medical Affairs Manager at Glaxo Research and Development Ltd. Ms Bevan is head
of PHLS Technical Services. Dr. Slade is Safety Advisor at King's College London. Dr. Own is now retired; he was the former Deputy
Director of Medical Services at the Health and Safety Executive. Mr. Taylor, Ms Smith and Mrs McGuire all work within the health
service.
We shall write to the hon. Member with further details of the commercial and non-commercial interests of the Chairman and members.
The ACDP is concerned with formulating advice on the infection risks of xenotransplantation. They have not been required to provide
advice on ethical issues, and their personal views are not known.
Subjects
Biotechnology; Ethics; Public appointments; Medicine; Xenotransplantation; Advisory Committee on Dangerous Pathogens
Date
12 January 1998
Reference
22629; 304 c144-5W
House
House of Commons